Historic Milestone: U.S. Senate Unanimously Passes National Plan for Epilepsy Act, Paving Way for Coordinated National Strategy

WASHINGTON D.C. – August 11, 2026 – In a monumental step lauded by patient advocates, healthcare professionals, and researchers across the nation, the U.S. Senate unanimously passed the National Plan for Epilepsy Act (S. 494) on August 4, 2026. This landmark legislation represents a historic turning point, committing the federal government to establish a comprehensive, coordinated national strategy aimed at profoundly improving epilepsy care, significantly advancing research, drastically reducing epilepsy-related deaths, and ultimately enhancing the quality of life for the millions of Americans living with this complex neurological condition.

The unanimous vote in the Senate underscores a burgeoning bipartisan recognition of epilepsy as a critical public health challenge demanding urgent and strategic intervention. It is the culmination of years, even decades, of tireless advocacy, relentless dedication, and powerful storytelling from individuals living with epilepsy, their families, caregivers, medical experts, and a wide array of epilepsy organizations. Their collective voice has successfully elevated the needs of a community too often overlooked and underserved, propelling this vital legislation forward.

Table of Contents

Main Facts: A Unified Front for a Forgotten Condition

Epilepsy, a chronic non-communicable brain disease characterized by recurrent, unprovoked seizures, affects an estimated 3.4 million Americans and approximately 65 million people worldwide. Despite its widespread prevalence, epilepsy has historically suffered from underfunding, fragmented care, and pervasive societal stigma. The National Plan for Epilepsy Act seeks to fundamentally change this landscape by establishing a cohesive federal framework to address the multifaceted challenges associated with the condition.

The core purpose of S. 494 is ambitious yet essential: to mandate a federal review of existing epilepsy programs across various agencies, identify critical gaps in services, research, and patient outcomes, and subsequently develop actionable recommendations to address these unmet needs. This strategic blueprint will focus on several key pillars:

Research Advancement: Accelerating scientific discovery into the causes, prevention, and improved treatments for epilepsy.

Diagnosis and Treatment Optimization: Ensuring timely and accurate diagnosis, and access to the most effective, personalized treatment options.

Awareness and Education: Combating stigma through public education and increasing understanding among healthcare providers and the general public.

Mortality Prevention: Implementing strategies to reduce epilepsy-related deaths, including Sudden Unexpected Death in Epilepsy (SUDEP).

Quality of Life Enhancement: Addressing the broader impacts of epilepsy on mental health, education, employment, and social well-being.

Crucially, the legislation ensures that the development and ongoing evolution of this National Plan will be informed by continuous input from those with lived experience, healthcare providers on the front lines, pioneering researchers, dedicated advocates, and relevant federal agencies. This inclusive approach guarantees that the strategy will remain patient-centric and responsive to the evolving needs of the epilepsy community. The unanimous Senate passage on August 4, 2026, marks an unprecedented moment of legislative consensus, signaling a nationwide commitment to finally prioritize epilepsy care and research.

Chronology: A Decade of Determination Culminating in Senate Victory

The journey to the Senate floor for the National Plan for Epilepsy Act has been a testament to enduring commitment and strategic legislative navigation. While the August 4th vote represents a critical climax, its origins can be traced back through years of groundwork laid by dedicated advocates and legislative champions.

Early Advocacy and Foundational Work

The concept of a national, coordinated strategy for epilepsy is not new. For decades, various patient organizations, including Epilepsy Alliance America and its predecessors, have called for a more unified approach to address the fragmented landscape of epilepsy care and research. These early efforts often involved raising awareness about the significant gaps in funding for epilepsy research compared to other neurological conditions, highlighting disparities in access to specialized care, and advocating for a clearer federal roadmap. The idea gained significant traction through grassroots campaigns, where individuals bravely shared their personal stories, illustrating the profound impact of epilepsy on daily life and the urgent need for systemic change. These foundational efforts coalesced into the "Epilepsy Community Consensus Priorities" earlier this year, a critical document that provided a unified vision and specific recommendations for what a national plan should encompass, directly informing the legislative text of S. 494.

Legislative Introduction and Committee Review

The National Plan for Epilepsy Act, designated S. 494 in the Senate, was introduced with strong bipartisan sponsorship, reflecting the broad appeal of its mission. Senators Eric Schmitt (R-MO) and Amy Klobuchar (D-MN) emerged as key bipartisan leaders, championing the bill through the intricate legislative process. Their commitment highlighted the non-partisan nature of health advocacy, uniting lawmakers across the aisle in support of a common cause.

A pivotal moment occurred on July 22, 2026, when the Senate Health, Education, Labor and Pensions (HELP) Committee, a powerful committee overseeing health policy, approved a Manager’s Amendment to S. 494. A Manager’s Amendment is a comprehensive amendment offered by the committee chair or ranking member, often incorporating technical fixes, refining language, or adding provisions agreed upon by committee members. In this instance, the Manager’s Amendment was crucial as it "preserved the bill’s core purpose while strengthening its framework." This careful refinement ensured the legislation was robust, comprehensive, and ready for consideration by the full Senate, reflecting a thoughtful and collaborative legislative process. The committee’s approval signaled a strong consensus and momentum building for the bill.

Unanimous Senate Passage

The culmination of these efforts arrived on August 4, 2026, when the National Plan for Epilepsy Act was brought to the floor of the U.S. Senate. In a rare display of complete legislative unity, the bill passed unanimously. This resounding support, with not a single dissenting vote, sent a powerful message about the perceived necessity and merit of the legislation. Such unanimous consent is uncommon in today’s often-divided political climate and underscores the compelling case made by advocates and the undeniable need for a national strategy to tackle epilepsy. The unanimous passage serves not only as a legislative victory but also as a symbolic affirmation of the national commitment to address epilepsy as a serious public health priority.

The Path Ahead: Mobilizing for House Passage

While the Senate’s approval is a monumental achievement, the legislative journey for S. 494 is not yet complete. The bill now moves to the U.S. House of Representatives, where it must also pass before it can be sent to the President to be signed into law. This next phase requires sustained advocacy and continued mobilization from the epilepsy community and its congressional champions. The momentum from the Senate’s unanimous vote is expected to significantly bolster its prospects in the House, but vigilance and proactive engagement remain paramount.

Supporting Data: The Urgent Need for a National Plan

The imperative for a National Plan for Epilepsy is starkly evident when examining the current landscape of the condition in the United States. Despite its widespread impact, epilepsy remains one of the least understood and most undertreated serious neurological disorders.

Prevalence and Profound Impact

As noted, approximately 3.4 million Americans live with epilepsy, a number comparable to the prevalence of Alzheimer’s disease and Parkinson’s disease combined, yet it often receives significantly less public attention and research funding. Estimates suggest that nearly 1 in 26 people will develop epilepsy at some point in their lives. The condition manifests in myriad ways, with over 40 different types of seizures and numerous epilepsy syndromes, making diagnosis and treatment complex and highly individualized. The impact extends far beyond the seizures themselves, permeating every aspect of an individual’s life, from education and employment to social interactions and mental well-being.

Alarming Mortality Rates

Epilepsy is not just a chronic condition; it carries a significant risk of premature mortality. Studies indicate that the overall mortality rate for people with epilepsy is two to three times higher than that of the general population. A leading cause of death in this population is Sudden Unexpected Death in Epilepsy (SUDEP), which accounts for approximately 1 in 1,000 epilepsy deaths annually. SUDEP is often poorly understood, under-reported, and a source of profound fear and anxiety for patients and families. Beyond SUDEP, epilepsy-related deaths can also result from prolonged seizures (status epilepticus), accidents during seizures (e.g., drowning, falls), and complications from co-occurring conditions. The lack of a coordinated national effort to understand, prevent, and educate about these risks has contributed to these preventable deaths.

Pervasive Quality of Life Challenges and Co-morbidities

The "challenges that extend far beyond seizures" highlighted by advocates are pervasive. Individuals with epilepsy frequently experience significant co-morbidities, including depression, anxiety, and other mental health disorders, with prevalence rates significantly higher than in the general population. Cognitive impairments, memory issues, and learning difficulties are also common, impacting educational attainment and employment opportunities. Social stigma remains a formidable barrier, leading to discrimination, isolation, and a reluctance to disclose the condition, which can further hinder access to support and care.

Economic Burden and Healthcare Disparities

The economic burden of epilepsy is substantial. Direct medical costs, including hospitalizations, emergency room visits, physician services, and medications, are estimated to be in the billions of dollars annually. Indirect costs, such as lost wages due to unemployment or underemployment, caregiver burden, and reduced productivity, further amplify the financial strain on individuals, families, and the healthcare system.

Moreover, significant disparities exist in access to specialized epilepsy care. Many regions, particularly rural and underserved areas, lack sufficient numbers of neurologists specializing in epilepsy or access to comprehensive epilepsy centers. This forces patients to travel long distances or forgo specialized care, leading to delayed diagnoses, suboptimal treatment, and poorer outcomes. The current fragmented system often fails to provide integrated care that addresses the full spectrum of physical, psychological, and social needs of people with epilepsy.

Gaps in Research and Public Awareness

Despite advancements, fundamental questions about the causes of epilepsy, mechanisms of seizure generation, and development of curative therapies remain unanswered. Research funding, while increasing, has historically lagged behind other neurological conditions of similar prevalence and impact. Furthermore, public awareness of epilepsy remains alarmingly low, contributing to misconceptions, fear, and stigma. Many still believe epilepsy is contagious or a sign of mental illness, hindering early intervention and social integration.

This compelling body of evidence underscores the critical necessity of the National Plan for Epilepsy Act. It represents a strategic imperative to bridge these gaps, alleviate suffering, reduce mortality, and ultimately transform the lives of millions affected by this challenging condition.

Official Responses: Voices of Advocacy and Leadership

The unanimous Senate passage has been met with an outpouring of gratitude and renewed determination from the epilepsy community. Key leaders and advocates have voiced their profound appreciation for the legislative progress while emphasizing the critical work that lies ahead.

Liza Gundell, Board Chair of Epilepsy Alliance America, articulated the deep significance of this moment: "We are grateful to Senators Eric Schmitt and Amy Klobuchar for their bipartisan leadership and commitment to improving the lives of people affected by epilepsy. The Senate’s unanimous support demonstrates a growing recognition that epilepsy deserves a coordinated national response. For too many individuals and families, epilepsy brings challenges that extend far beyond seizures, including barriers to care, stigma, financial burdens, and concerns about safety and quality of life. A National Plan for Epilepsy will help ensure that these challenges are addressed through a thoughtful, comprehensive, and collaborative strategy." Ms. Gundell’s remarks highlight not only the legislative triumph but also the profound humanitarian impact this plan is expected to have, finally providing a systemic approach to problems that have long been shouldered by individuals and their immediate support networks. Her emphasis on the "thoughtful, comprehensive, and collaborative strategy" speaks to the robust framework envisioned by the bill, moving beyond piecemeal solutions to a truly integrated system of care and support.

The bipartisan champions, Senators Eric Schmitt and Amy Klobuchar, though not quoted directly in the initial announcement, are understood to have been instrumental. Their leadership reflects a deep understanding of the public health implications of epilepsy and a commitment to their constituents’ well-being. Senator Klobuchar, known for her dedication to healthcare access and patient advocacy, likely championed the bill from a perspective of ensuring equitable care and support for all Americans. Senator Schmitt, whose focus often includes improving healthcare systems and supporting vulnerable populations, would have seen the National Plan as a crucial investment in public health and economic stability. Their collaboration across the political spectrum underscores the universal recognition of epilepsy’s impact.

While celebrating the Senate’s achievement, Lisa Gallipoli, Executive Director of Epilepsy Alliance America, delivered a powerful call to continued action: "The passage by the Senate of the National Plan for Epilepsy is a great achievement; but our work is not done! Epilepsy Alliance America is proud to be part of the greater epilepsy community, speaking and acting in one shared voice, about the National Plan for Epilepsy. We will continue to mobilize our network to ensure that the House of Representatives follows the lead of the Senate before the end of the Congressional term." Ms. Gallipoli’s statement serves as a vital reminder that legislative victories are often multi-stage processes. Her emphasis on the "shared voice" of the epilepsy community highlights the strength derived from unity and the strategic importance of sustained grassroots mobilization to secure passage in the House. Her words resonate with the understanding that the finish line is in sight, but not yet crossed.

The personal connection to the cause was poignantly articulated by Amanda Mitchell, MPH, an Epilepsy Alliance America Board member and member of the National Plan for Epilepsy Committee, who helped draft The Epilepsy Community Consensus Priorities. "As the parent of a child with epilepsy, advocating for the National Plan for Epilepsy is deeply personal to me. I know just how desperately our community needs the investments in comprehensive research, effective treatments, improved access to care, and increased support. It has been a privilege to add my voice to those in the epilepsy community who have pushed for this change for many years. I look forward to continuing to support this work until the plan is enacted into law, and we see its benefits for the millions of Americans living with epilepsy." Ms. Mitchell’s powerful testimony underscores the lived experience driving this advocacy. Her direct involvement in shaping the consensus priorities means her perspective is not just emotional but also informed by a deep understanding of the practical needs and systemic changes required. Her commitment to seeing the plan through to enactment reflects the enduring hope and resolve of families affected by epilepsy.

From a scientific perspective, a (hypothetical) leading neuroscientist might have commented, "This National Plan for Epilepsy Act will be a game-changer for research. By fostering greater collaboration across federal agencies and earmarking dedicated resources, we can accelerate our understanding of epilepsy’s complex mechanisms. This isn’t just about incremental progress; it’s about catalyzing breakthroughs that could lead to new diagnostics, more effective therapies, and even cures, ultimately transforming the prognosis for millions." Such a statement would further solidify the scientific community’s support and the transformative potential of the legislation.

These official responses collectively paint a picture of immense relief, profound gratitude, and unwavering determination. They celebrate a historic achievement while simultaneously recognizing the imperative of continued advocacy to translate this legislative victory into tangible improvements for the epilepsy community.

Implications: A Future Transformed for Millions

The unanimous passage of the National Plan for Epilepsy Act by the Senate carries profound implications, signaling a potential paradigm shift in how epilepsy is addressed in the United States. Its enactment promises to reshape the landscape of epilepsy care, research, and public perception for decades to come.

Transformative Impact on Patients and Families

For the millions of Americans living with epilepsy and their families, the most immediate and impactful implication will be the promise of improved outcomes. A coordinated national strategy is expected to lead to:

Earlier and More Accurate Diagnosis: By promoting better education for healthcare providers and increasing awareness, the plan aims to reduce diagnostic delays, allowing for earlier intervention.
Enhanced Access to Specialized Care: The identification of service gaps and development of recommendations will facilitate the expansion of comprehensive epilepsy centers and specialized neurological care, particularly in underserved regions.
Reduced Mortality: Focused efforts on understanding and preventing SUDEP, along with better seizure management, are expected to significantly lower epilepsy-related deaths.
Improved Quality of Life: By addressing co-morbidities like mental health challenges, combating stigma, and providing better support systems, the plan will help individuals with epilepsy lead fuller, more integrated lives. This includes fostering educational attainment and employment opportunities, breaking down barriers that have historically limited their potential.

Reshaping the Healthcare System

The National Plan will instigate a significant evolution within the healthcare system’s approach to epilepsy:

Integrated Care Models: The emphasis on identifying gaps and developing recommendations will likely lead to more integrated care models, ensuring that patients receive holistic support encompassing medical, psychological, and social services.
Standardized Protocols: The plan could drive the development of national best practice guidelines for epilepsy management, ensuring a more consistent and higher quality of care across diverse healthcare settings.
Enhanced Professional Training: Increased awareness and focused initiatives may lead to better training for general practitioners, emergency responders, and other healthcare professionals, improving initial responses and ongoing management of epilepsy.

Accelerating Research and Discovery

One of the most exciting implications lies in the realm of scientific research. A national plan will:

Increase Funding and Coordination: By establishing epilepsy as a national priority, the plan is expected to unlock greater and more stable federal funding for epilepsy research. More importantly, it will foster unprecedented coordination among various research institutions, federal agencies (like NIH, CDC), and private foundations, minimizing duplication and maximizing impact.
Targeted Research Priorities: The plan will identify critical research gaps and prioritize areas such as the causes of different epilepsy types, the development of new anti-seizure medications with fewer side effects, non-pharmacological interventions, and ultimately, a cure.
Faster Translation of Discoveries: Coordinated efforts can accelerate the translation of basic scientific discoveries into clinical applications, bringing new treatments and diagnostic tools to patients more quickly.

Fostering Public Awareness and Stigma Reduction

A crucial element of the National Plan will be its focus on awareness. By leveraging federal resources, the plan can:

Launch National Education Campaigns: These campaigns can dismantle myths and misconceptions surrounding epilepsy, fostering greater understanding and empathy in the general public.
Reduce Stigma: By normalizing discussions around epilepsy and showcasing the capabilities of individuals living with the condition, the plan can significantly reduce the pervasive stigma that has long plagued the community. This will empower individuals to seek help, participate more fully in society, and improve their overall well-being.

Economic Benefits

While the primary focus is on health and quality of life, the long-term economic implications are also significant. By improving health outcomes, reducing hospitalizations, and increasing workforce participation, the National Plan is expected to:

Reduce Healthcare Costs: Better management of epilepsy can lead to fewer emergency room visits, hospital stays, and complications, thereby reducing direct healthcare expenditures.
Increase Productivity: Empowering individuals with epilepsy to achieve better health and manage their condition effectively will enable greater participation in the workforce, boosting economic productivity and reducing indirect costs associated with disability.

The Road Ahead: From Legislation to Lived Reality

Despite the euphoria surrounding the Senate’s unanimous vote, the work is far from over. The bill must now secure passage in the U.S. House of Representatives. Epilepsy Alliance America has already identified champions in the House, including Representatives Jim Costa (CA-21) and Greg Murphy, M.D. (NC-3), who will be crucial in steering the legislation through the lower chamber. Their efforts, combined with sustained grassroots advocacy, will be essential to ensure the House follows the Senate’s lead before the end of the current Congressional term.

Even after presidential enactment, the real work of implementation will begin. This will require sustained funding, diligent oversight, and continuous input from the epilepsy community to ensure the National Plan is effective, adaptable, and truly responsive to the needs it aims to serve. The passage of S. 494 by the Senate is not an end but a powerful beginning—a promise of a brighter, healthier, and more equitable future for all Americans affected by epilepsy. The call to action remains clear: continued engagement with U.S. Representatives is vital to transform this historic legislative triumph into a lasting legacy of improved lives.